UK Reviews Palantir NHS Contract
Analysis based on 20 articles · First reported Jun 02, 2026 · Last updated Jun 09, 2026
The ongoing review of Palantir>>>'s contract with the United Kingdom — National Health Service>>> and the potential for its termination could negatively impact Palantir>>>'s stock price and future public sector contracts. Concerns about reliance on foreign tech firms and data handling may lead to increased scrutiny for other U.S. tech companies seeking government contracts in the United Kingdom>>>.
The United Kingdom>>> government is conducting a full review of its £330 million contract with U.S. data analytics firm Palantir>>> for the United Kingdom — National Health Service>>>. This comes amidst growing political pressure from a parliamentary committee, which urged ministers to use a break clause in early 2027, citing concerns about over-reliance on U.S. tech companies, potential risks to sensitive data, and a 'mismatch with UK values'. The committee highlighted Palantir>>>'s work with the U.S. military and immigration authorities, as well as the political views of its co-founder, Peter Thiel>>>. Technology minister Liz Kendall>>> confirmed the review, which will assess whether to extend the deal for up to seven years or terminate it. Separately, United Kingdom — London>>> Mayor Sadiq Khan>>> blocked a police contract with Palantir>>> due to value for money and ethical concerns. Palantir>>>'s British CEO, Louis Mosley>>>, defended the contract, stating its cancellation would be irresponsible. The controversy has led to pullbacks in Palantir>>>'s stock.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard